Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy

Vaccine

Volumn 31, Issue 42, 2013, Pages 4782-4790

  Abzug, Mark J ^a   Song, Lin Ye ^b   Levin, Myron J ^a   Nachman, Sharon A ^c   Borkowsky, William ^d   Pelton, Stephen I ^e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Children; HIV; Memory; Pneumococcal; Vaccine

Indexed keywords

ANTIBODY; ANTIRETROVIRUS AGENT; CD19 ANTIGEN; CD4 ANTIGEN; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; VACCINATION; VIRUS LOAD;

CHILDREN; HIV; MEMORY; PCV; PNEUMOCOCCAL; PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; PPV; VACCINE; VIRAL LOAD; VL;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION; YOUNG ADULT;

EID: 84884210477     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.002     Document Type: Article

References (31)

1. Abzug M.J., Pelton S.I. Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox. Journal of Infectious Diseases 2009, 199:1109-1111.
2. Flannery B., Heffernan R.T., Harrison L.H., Ray S.M., Reingold A.L., Hadler J., et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Annals of Internal Medicine 2006, 144:1-9.
3. Albrich W.C., Baughman W., Schmotzer B., Farley M.M. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clinical Infectious Diseases 2007, 44:1569-1576.
4. Nunes M.C., von Gottberg A., de Gouveia L., Cohen C., Moore D.P., Klugman K.P., et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 2011, 25:453-462.
5. Madhi S.A., Klugman K.P., Kuwanda L., Cutland C., Käyhty H., Quantitative Adrian P. qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. Journal of Infectious Diseases 2009, 199:1168-1176.
6. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H., et al. A trial of 7-valent pneumococcal conjugate vaccine in HIV-infected adults. New England Journal of Medicine 2010, 362:812-822.
7. Madhi S.A., Adrian P., Kuwanda L., Jassat W., Jones S., Little T., et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007, 25:2451-2457.
8. Abzug M.J., Pelton S.I., Song L., Fenton T., Levin M.J., Nachman S.A., et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatric Infectious Disease Journal 2006, 25:920-929.
9. Abzug M.J., Warshaw M., Rosenblatt H.M., Levin M.J., Nachman S.A., Pelton S.I., et al. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2009, 200:935-946.
10. Abzug M.J., Qin M., Levin M.J., Fenton T., Beeler J.A., Bellini W.J., et al. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2012, 206:512-522.
11. Klugman K.P., Madhi S.A., Adegbola R.A., Cutts F., Greenwood B., Hausdorff W.P. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine 2011, 29:3372-3373.
12. Wuorimaa T., Dagan R., Väkeväinen M., Bailleux F., Haikala R., Yaich M., et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect. Dis. 2001, 184:1211-1215.
13. Recommendations to assure the quality, safety, and efficacy of pneumococcal conjugate vaccines. 60th Meeting of the WHO Expert Committee on Biological Standardization 2009, Available at: http://www.who.int/biologicals/areas/vaccines/pneumo/Pneumo_final_23APRIL_2010.pdf (accessed 3.7.13).
14. Tarrago D., Casal J., Ruiz-Contreras J., Ramos J.T., Rojo P., Snippe H., et al. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clinical and Diagnostic Laboratory Immunology 2005, 12:165-170.
15. Madhi S.A., Kuwanda L., Cutland C., Holm A., Käyhty H., Klugman K.P. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatric Infectious Disease Journal 2005, 24:410-416.
16. McVernon J., Johnson P.D., Pollard A.J., Slack M.P., Moxon E.R. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Archives of Disease in Childhood 2003, 88:379-383.
17. Blanchard Rohner G., Snape M.D., Kelly D.F., John T., Morant A., Yu L.M., et al. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. Journal of Immunology 2008, 180:2165-2173.
18. O'Brien K.L., Hochmann M., Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue. Lancet Infectious Diseases 2007, 7:597-606.
19. Usinger W.R., Lucas A.H. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infection and Immunity 1999, 67:2366-2370.
20. Antttila M., Voutilainen M., Jantti V., Eskola J., Kayhty H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clinical and Experimental Immunology 1999, 118:402-407.
21. Thanee C., Pancharoen C., Likitnukul S., Luangwedchakarn V., Umrod P., Phasomsap C., et al. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. Vaccine 2011, 29:5886-5891.
22. Spoulou V.I., Tsoumas D.L., Papaevangelou V.G., Mostrou G.I., Theodoridou M.C. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine 2005, 23:5289-5293.
23. Feikin D.R., Elie C.M., Goetz M.B., Lennox J.L., Carlone G.M., Romero-Steiner S., et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2002, 20:545-553.
24. Spoulou V.I., Tsoumas D.L., Papaevangelou V.G., Mostrou G.I., Theodoridou M.C. Haemophilus influenza type b conjugate vaccine-induced immunological memory in symptomatic HIV-1-infected children. AIDS 2003, 17:1396-1398.
25. Rutstein R.M., Rudy B.J., Cnaan A. Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenza type b conjugate vaccine. Archives of Pediatrics & Adolescent Medicine 1996, 150:838-842.
26. Bliss S.J., O'Brien K.L., Janoff E.N., Cotton M.F., Musoke P., Coovadia H., et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infectious Diseases 2007, 8:67-80.
27. Hart M., Steel A., Clark S.A., Moyle G., Nelson M., Henderson D.C., et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. Journal of Immunology 2007, 178:8212-8220.
28. Titanji K., de Milito A., Cagigi A., Thorstensson R., Grützmeier S., Atlas A., et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006, 108:1580-1587.
29. D'Orsogna L.J., Krueger R.G., McKinnon E.J., French M.A. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS 2007, 21:1747-1752.
30. Iwajomo O.H., Finn A., Moons P., Nkhata R., Sepako E., Ogunniyi A.D., et al. Deteriorating pneumococcal-specific B-cell memory in minimally symptomatic African children with HIV infection. Journal of Infectious Diseases 2011, 204:534-543.
31. Madhi S.A., Adrian P., Cotton M.F., McIntyre J.A., Jean-Philippe P., Meadows S., et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. Journal of Infectious Diseases 2010, 202:355-361.